Fierce Pharma

SEPTEMBER 7, 2023

Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.

Biopharma 337

Biopharma Pharma 337

Fierce Pharma

JANUARY 3, 2024

Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024. As the J.P. | As the J.P.

Biopharma 346

Biopharma Sales Healthcare Healthcare 346

Zymewire

JULY 24, 2024

As the second quarter of 2024 comes to a close, the biopharma landscape continues to evolve with dynamic shifts in funding, clinical trials, and innovative developments. Zymewire is back to provide you with a comprehensive digest of what's happened in Q2, to help inform smarter business decisions going forward.

Biopharma 52

Biopharma 52

Fierce Pharma

APRIL 11, 2024

As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001.

Biopharma 326

Biopharma Pharma 326

Fierce Pharma

JUNE 11, 2024

Amid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent splashes.

Biopharma 313

Biopharma Healthcare Healthcare 313

Pharmaceutical Technology

AUGUST 20, 2024

The top 20 biopharmaceutical companies demonstrated resilience during the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve.

Marketing 105

Marketing Biopharma 105

Fierce Pharma

MAY 2, 2024

With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based biopharma is busy laying the groundwork for its next potential mRNA shot in | Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, the company said Thursday.

Biopharma 274

Biopharma Sales Marketing 274

MedCity News

FEBRUARY 16, 2024

Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!

Healthcare 96

Healthcare Healthcare Biopharma Networking 96

Pharmaceutical Commerce

JANUARY 26, 2024

A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation.

Biopharma 52

Biopharma 52

Fierce Pharma

DECEMBER 19, 2023

As the biopharma world readies for the turn of the calendar, the all-too-familiar topic of drug pricing once again presents an industry-wide overhang. Based on the series of measures centered on U.S. drug prices coming out of Washington, the Biden administration is clearly emboldened on the topic.

Biopharma 190

Biopharma Pharma 190

European Pharmaceutical Review

JUNE 28, 2024

A holistic approach to safeguard data integrity in biopharma manufacturing Data integrity is critical in biopharma manufacturing yet is often difficult to achieve due to complex regulatory requirements and legacy data management systems, among the many factors. Interested? Register your details to access this exclusive content.

Biopharma 52

Biopharma Manufacturing Safety Pharmaceutical 52

PharmaTech

JUNE 3, 2024

The PharmTech Group spoke with Stacey Treichler, senior director of Marketing and Strategy for Purolite at Ecolab, about the impact of advanced therapies, new innovations, and sustainability on the biopharmaceutical industry.

Biopharma 64

Biopharma Marketing 64

PharmaVoice

JANUARY 18, 2024

Creative thinking is the name of the game as biopharmas seek to overcome a host of challenges — and investing with purpose, building trust and embracing tech could get them there.

Biopharma 52

Biopharma 52

Pharmaceutical Commerce

NOVEMBER 14, 2023

Woerner, PhD, director and principal research scientist at the MIT Center for Information Systems Research, discusses the outlook for next year among biopharma firms. Stephanie L.

Biopharma 52

Biopharma 52

PharmExec

JANUARY 26, 2024

A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation.

Biopharma 40

Biopharma 40

Zymewire

APRIL 22, 2024

Summary of funding events, FDA approvals, clinical trial stats, and upcoming research and development plans from the world of biotech and pharma in Q1 2024

Biopharma 52

Biopharma FDA Pharma 52

PharmaTech

OCTOBER 8, 2024

Stacey Treichler, senior director of global marketing and strategy, Purolite, an Ecolab company, spoke about current trends in the biopharma industry and innovations in purification resins at CPHI Milan.

Biopharma 52

Biopharma Marketing 52

PharmaVoice

OCTOBER 16, 2023

A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

Biopharma 52

Biopharma 52

Pharmaceutical Technology

OCTOBER 12, 2022

Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. TRG035’s Phase I clinical study is scheduled to begin in early 2024.

Biopharma 52

Biopharma Manufacturing Pharmaceutical Marketing 52

pharmaphorum

JANUARY 26, 2024

ArriVent BioPharma completes the second biotech IPO of 2024, raising $175m that will help advance its late-stage lung cancer drug furmonertinib

Biopharma 102

Biopharma 102

PM360

MAY 23, 2024

Bryan Johnson Senior Director, Product Management, Compass Prescriber Veeva Systems Paving the Way to Faster Treatment Starts Bryan’s exposure to life sciences started at a young age, watching his father’s career at companies like Johnson & Johnson and emerging biopharmas.

Retail 52

Retail Biopharma Prescription Healthcare Provider 52

PharmExec

JUNE 14, 2024

Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings such as GLP-1s, Pharm Exec’s latest listing of the top global biopharma sales producers is proof-positive of an industry in transition.

Biopharma 52

Biopharma Sales 52

PharmaVoice

JANUARY 8, 2024

New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

Biopharma 75

Biopharma FDA 75

MedCity News

MARCH 6, 2024

Will 2024 bring any change, or will we witness yet another record- and heart-breaking year of preventable deaths?

Biopharma 116

Biopharma 116

pharmaphorum

APRIL 10, 2024

It is the largest acquisition in the biopharma sector so far in 2024. The $65-per-share deal is due to close within the next three months, said Vertex, which plans to fund the acquisition with cash in hand.

Biopharma 103

Biopharma Medicine Pharma 103

MedCity News

NOVEMBER 1, 2023

MedCity News is inviting startups to apply for the INVEST 2024 Pitch Perfect Startup Contest on May 21-22 at the annual INVEST conference in the Ritz Carlton hotel in Chicago.

Biopharma 100

Biopharma 100

PharmExec

JANUARY 17, 2024

Generative artificial intelligence, key new product launches, and the evolution of the go-to-market model are among key trends to watch in the year ahead.

Biopharma 40

Biopharma Marketing 40

PharmaTech

JUNE 5, 2024

Pharmaceutical Technology® spoke with Parviz Shamlou, senior vice-president of Science and Technology, Abzena, about the impact of the Biosecure Act on the bio/pharmaceutical industry, as well as the progress of continuous manufacturing in biopharma.

Biopharma 52

Biopharma Pharma Manufacturing Pharmaceutical 52

MedCity News

FEBRUARY 4, 2024

2024 stands at a critical juncture in the battle against soaring pharmacy costs. 2024 can finally be the year when policy shifts and proactive employer preferences align, creating a landscape where PBMs can no longer hide behind opaque practices and a status-quo mentality.

Prescription 102

Prescription Networking Management Pharmaceutical 102

MedCity News

FEBRUARY 14, 2024

2024 presents an exciting yet challenging landscape for global pharma marketers.

Marketing 98

Marketing Pharma Pharmaceutical Patients 98

Clarivate

APRIL 18, 2024

In 2024, watch as the global trendsetter brings to bear its technological expertise combined with a captive Prime membership, brand recognition, and national employer buy-in to re-envision healthcare that truly works around the patient. Healthcare segment) across the nation as part of a $1 billion cost-cutting strategy.

Retail 52

Retail Healthcare Healthcare Physicians 52

Pharmaceutical Technology

APRIL 26, 2024

The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.

Biopharma 52

Biopharma Marketing 52

Pharmaceutical Technology

NOVEMBER 17, 2023

Following the agreement, ABVC BioPharma will hold 57% of the consolidated shares of AiBtl, which plans to go IPO in 2024.

Biopharma 52

Biopharma 52

Clarivate

JANUARY 8, 2024

The annual Clarivate Drugs to Watch report for 2024 features 13 new therapeutics with standout commercial and/or clinical potential. The year 2024 is shaping up to be the best of times and the worst of times for the pharma industry,” said Henry Levy, President, Life Sciences & Healthcare at Clarivate.

Marketing 59

Marketing Patients Healthcare Healthcare 59

MedCity News

SEPTEMBER 18, 2024

An FDA decision for the topical cream in atopic dermatitis is expected by the end of 2024. By acquiring Dermavant, Organon gets Vtama, a drug approved for treating plaque psoriasis. The post Organon Gets More Skin in the Game by Acquiring Roivant’s Dermatology Subsidiary appeared first on MedCity News.

FDA 119

FDA Biopharma Pharma 119

European Pharmaceutical Review

MARCH 15, 2024

The research also explained that an increased focus on developing novel drugs to treat various chronic and life-threatening diseases is putting pressure on biopharma companies to launch new products in the market under strict regulatory timelines. percent of the market share in 2024, the report stated. It is predicted to hold over 35.7

Marketing 98

Marketing Biopharma Government Pharmaceutical 98

MedCity News

FEBRUARY 29, 2024

While the past several decades have seen progress in early detection, recent innovations in metastatic breast cancer—or cancer that has spread to distant parts of the body, including the bone, brain, or lungs—continues to cause excitement.

Biopharma 110

Biopharma 110